Matchpoint – Ponatinib and Intensive Chemotherapy [UK]
Study title
Matchpoint – Ponatinib and Intensive Chemotherapy
Scientific title
Management of Transformed Chronic myeloid leukaemia: Ponatinib and intensive chemotherapy: a dose finding study (Clinicaltrialsregister.eu 2012-005629-65)
Type of study
Treatment of advanced phases
Current status
No longer recruiting
What is the purpose of the study
The aim of this trial is to find a safe and effective dose of a drug called ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase.
Key inclusion criteria
Male or female patients of 16 years of age or older with Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) in blast phase (BP).
Patients can be considered for inclusion in the study if they are suitable for intensive chemotherapy, have adequate kidney and liver function as well as normal pancreas function.
Key exclusion criteria
Where can I find additional information
Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)
Study sponsor
University of Birmingham
Scientific lead / contact
Professor Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD
Principal investigator
Prof. Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD
Study centers / principal investigators
United Kingdom
University of Birmingham
CRCTU, Institute of Cancer and Genomic Sciences
Edgbaston, B15 2TH
Glasgow
Leeds
Liverpool
London
Nottingham